Gurgaon Samachar

Pioneering the Fight against Non-Small Cell Lung Cancer Pipeline: A Comprehensive Pipeline Review | Companies – BridgeBio Pharma, Daiichi Sankyo, Merck, Abbvie, Pfizer, Eli Lilly and Others

 Breaking News
  • No posts were found

Pioneering the Fight against Non-Small Cell Lung Cancer Pipeline: A Comprehensive Pipeline Review | Companies – BridgeBio Pharma, Daiichi Sankyo, Merck, Abbvie, Pfizer, Eli Lilly and Others

June 02
21:50 2023
Pioneering the Fight against Non-Small Cell Lung Cancer Pipeline: A Comprehensive Pipeline Review | Companies - BridgeBio Pharma, Daiichi Sankyo, Merck, Abbvie, Pfizer, Eli Lilly and Others

DelveInsight’s, Non-Small-Cell Lung cancer Pipeline Insight 2023” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in Non-Small-Cell Lung cancer pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Non-Small Cell Lung Cancer Pipeline Outlook

 

Non-Small Cell Lung Cancer Overview

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45.

 

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Non-Small Cell Lung Cancer Pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small Cell Lung Cancer.
  • The leading Non-Small Cell Lung Cancer Companies include BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech,  and others.
  • Promising Non-Small Cell Lung Cancer Pipeline Therapies include INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
  • In Oct 2022, BerGenBio announced that they had begun the phase Ib/IIa trial evaluating bemcentinib in first-line non-small cell lung cancer patients with STK11 mutations.
  • In Oct 2022, eftilagimod alpha has been given a fast-track designation by the FDA for use as the first-line treatment for patients with stage IIIB/IV non-small cell lung cancer when combined with pembrolizumab.
  • In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) entered an exclusive license agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398, was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.

 

For further information, refer to the detailed Non-Small Cell Lung Cancer Unmet Needs, Non-Small Cell Lung Cancer Market Drivers, and Market Barriers, click here for Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis

 

Non-Small Cell Lung Cancer Emerging Drugs Profile

 

  • Datopotamab deruxtecan: Daiichi Sankyo

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of three leading ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG13 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

 

  • JDQ443: Novartis

JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with advanced non-small cell lung cancer (NSCLC).

 

  • MRTX849: Mirati Therapeutics

Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, as the KRASG12C protein regenerates every 24–48 hours. Adagrasib is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer and pancreatic cancer.

 

  • INBRX-106: Inhibrx

INBRX-106 is a hexavalent product candidate agonist of OX40. OX40 is a co-stimulatory receptor expressed on immune cells that is enriched in the tumor microenvironment. OX40 ligand is a trimeric protein that activates OX40 signaling through clustering. INBRX-106 was engineered to bind and cluster six OX40 receptors and has been shown preclinically to significantly outperform bivalent antibodies in co-stimulatory capacity and anti-tumor activity.

 

Request a sample and discover the recent advances in Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Non-Small Cell Lung Cancer Treatment Landscape

 

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 135+ key companies which are developing the therapies for Non-Small-Cell Lung cancer (NSCLC). The companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.

 

Dive deep into rich insights for drugs for Non-Small Cell Lung Cancer Pipeline, click here @ Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

Scope of the Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Non-Small Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech,  and others.
  • Non-Small Cell Lung Cancer Pipeline Therapies- INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
  • Non-Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, and Route of Administration

 

Got Queries? Find out the related information on Non-Small Cell Lung Cancer Mergers and acquisitions, Non-Small Cell Lung Cancer Licensing Activities @ Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non-Small-Cell Lung cancer (NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Small-Cell Lung cancer (NSCLC)– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase III)
  8. Datopotamab deruxtecan: Daiichi Sankyo
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RMC-4630: REVOLUTION Medicines
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. GB 1211: BridgeBio Pharma
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. BBP 398: BridgeBio Pharma.
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  24. Non-Small-Cell Lung cancer (NSCLC) Key Products
  25. Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
  26. Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
  27. Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
  28. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  29. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  30. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services